<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04558957</url>
  </required_header>
  <id_info>
    <org_study_id>POLFLEB</org_study_id>
    <nct_id>NCT04558957</nct_id>
  </id_info>
  <brief_title>Clinical Study to Assess the Safety and Efficacy of Mechanochemical Ablation With Flebogrif in Patients With Great Saphenous Vein Insufficiency</brief_title>
  <acronym>POLFLEB</acronym>
  <official_title>Prospective, Multi-centre Clinical Study to Assess the Safety and Efficacy of Mechanochemical Ablation With the Use of Flebogrif in Patients With Great Saphenous Vein Insufficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Balton Sp.zo.o.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KCRI</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Balton Sp.zo.o.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to collect clinical data of patients in whom Flebogrif® will&#xD;
      have been used for mechanochemical ablation of incompetent veins in the follow-up period, as&#xD;
      related to the safety, clinical effectiveness, properties and advantages of Flebogrif®.&#xD;
&#xD;
      The proposed study is a prospective, multi-centre clinical trial assessing the safety,&#xD;
      efficacy and quality of Flebogrif® in a population of patients with the incompetent great&#xD;
      saphenous vein, who require surgical treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 8, 2019</start_date>
  <completion_date type="Anticipated">May 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary efficacy endpoint: Occlusion rate</measure>
    <time_frame>3 months</time_frame>
    <description>Primary efficacy endpoint: Occlusion rate of the great saphenous vein in the treated segment at 3 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary safety endpoint: Rate of SAE</measure>
    <time_frame>30 days after the procedure</time_frame>
    <description>Primary safety endpoint: Rate of serious adverse events within 30 days after the procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occlusion rate</measure>
    <time_frame>1, 6, 12, 18, 24 months</time_frame>
    <description>Occlusion rate of the great saphenous vein at 1, 6, 12, 18 and 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with no reflux in treated segment of the vein</measure>
    <time_frame>1, 3, 6, 12, 18, 24 months</time_frame>
    <description>Number of Participants with no reflux in the treated segment of the great saphenous vein at 1, 3, 6, 12, 18 and 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life by Aberdeen Varicose Vein Questionnaire</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Change in quality of life measured with the use of the Aberdeen Varicose Vein Questionnaire at 12 and 24 months&#xD;
Scale score: 0-100; higher score = worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical success - changes in rVCSS</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>Clinical success, defined as change in rVCSS classification (Revised Venous Clinical Severity Score) after 12 and 24 months&#xD;
Scale score 0-30; higher score = worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of pain during the procedure</measure>
    <time_frame>During procedure</time_frame>
    <description>Assessment of pain during the procedure (Visual Analogue Pain Scale, VAPS) ranging from 0 to 10. Pain assessed using the Visual Analogue Scale (range 0-10; 0 = no pain; 2 = mild pain, 4 = nagging, annoying pain; 6 = severe pain; 8 = very severe pain; 10 = unbearable pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of pain within 0-7 days after the procedure: Visual Analogue Scale</measure>
    <time_frame>0-7 days after procedure</time_frame>
    <description>Assessment of pain within 0-7 days after the procedure (VAPS 0-10, daily assessment). Pain assessed using the Visual Analogue Scale (range 0-10; 0 = no pain; 2 = mild pain, 4 = nagging, annoying pain; 6 = severe pain; 8 = very severe pain; 10 = unbearable pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the need for analgesic treatment</measure>
    <time_frame>0-7 days after procedure</time_frame>
    <description>Assessment of the need for analgesic treatment after the procedure (0-7 days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period needed to resume normal activities</measure>
    <time_frame>up to 2 years after the treatment</time_frame>
    <description>Period needed to resume normal activities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period needed to return to work (sick leave period)</measure>
    <time_frame>up to 2 years after the treatment</time_frame>
    <description>Period needed to return to work (sick leave period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications rate</measure>
    <time_frame>up to 2 years after the treatment</time_frame>
    <description>Complications rate including deep vein thrombosis, nerve damage, infections, etc.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Chronic Venous Insufficiency, CVI</condition>
  <arm_group>
    <arm_group_label>FLEBOGRIF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interventions will be performed using Flebogrif catheter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FLEBOGRIF</intervention_name>
    <description>The catheter is a device dedicated to mechano-chemical ablation of insufficient veins of the superficial system.</description>
    <arm_group_label>FLEBOGRIF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Study inclusion criteria:&#xD;
&#xD;
          1. Signing the Informed Consent Form by the patient found eligible for the treatment with&#xD;
             the mechanochemical method&#xD;
&#xD;
          2. The patient declares willingness to participate in the study and in the monitoring&#xD;
             visits envisaged in the study protocol&#xD;
&#xD;
          3. A patient with diagnosed varicose veins and diagnosed great saphenous vein (GSV)&#xD;
             insufficiency confirmed by ultrasound (CEAP class C2-C6)&#xD;
&#xD;
          4. Favourable anatomy enabling the introduction of the Flebogrif® guidewire/catheter and&#xD;
             positioning of its top part at the dedicated site (2-3 cm below SFJ)&#xD;
&#xD;
          5. Diameter of the treated vein of 4-10 mm&#xD;
&#xD;
          6. No data or no history indicating an allergy to the sclerosing chemicals used in the&#xD;
             mechanochemical method (polidocanol), on the basis of the information obtained from&#xD;
             the patient and the available medical records&#xD;
&#xD;
          7. No clinical symptoms indicating (chronic, critical) lower limb ischaemia precluding&#xD;
             the use of compression, on the basis of a physical examination or, in unclear cases,&#xD;
             of a Doppler ultrasound examination&#xD;
&#xD;
          8. No medical information or no history of coagulation system dysfunction of the type of&#xD;
             thrombophilia or bleeding diatheses&#xD;
&#xD;
          9. No cutaneous lesions (purulent, bullous) within the limb found eligible for treatment&#xD;
             with the mechanochemical method&#xD;
&#xD;
         10. No clinical data indicating recent thrombosis within the deep vein system&#xD;
&#xD;
         11. No clinical data on diabetes with vascular complications&#xD;
&#xD;
         12. No clinical data indicating an active neoplastic process&#xD;
&#xD;
        Study exclusion criteria:&#xD;
&#xD;
          1. Recent deep vein thrombosis or occlusion&#xD;
&#xD;
          2. Congenital disorders with associated occlusion of deep system veins&#xD;
&#xD;
          3. Pregnancy and breast-feeding&#xD;
&#xD;
          4. Lower limb ischaemia&#xD;
&#xD;
          5. Severe lymphatic oedema&#xD;
&#xD;
          6. Bleeding diatheses&#xD;
&#xD;
          7. Documented allergic reaction to sclerosing chemicals used in mechanochemical vein&#xD;
             ablation&#xD;
&#xD;
          8. Purulent dermatoses affecting the limb found eligible for treatment with&#xD;
             mechanochemical vein ablation&#xD;
&#xD;
          9. Previous procedures on insufficiency veins of the superficial system&#xD;
&#xD;
         10. Acute infection&#xD;
&#xD;
         11. History of great saphenous vein thrombosis&#xD;
&#xD;
         12. End-stage kidney disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elżbieta Sojka</last_name>
    <phone>+48 22 597 44 43</phone>
    <email>elzbieta.sojka@balton.pl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centrum Chirurgii i Stomatologii Jaworuccy Sp. P.</name>
      <address>
        <city>Gorzów Wielkopolski</city>
        <zip>66-400</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleksandra Jaworucka-Kaczorowska, MD</last_name>
    </contact>
    <investigator>
      <last_name>Aleksandra Jaworucka-Kaczorowska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Angelius Provita; Europejskie Centrum Flebologii</name>
      <address>
        <city>Katowice</city>
        <zip>40-611</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomasz Urbanek, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Tomasz Urbanek, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medyczne Centrum Nałęczów sp. z o.o.</name>
      <address>
        <city>Lublin</city>
        <zip>20-950</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomasz Zubilewicz, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Tomasz Zubilewicz, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinika Dorobisz</name>
      <address>
        <city>Wrocław</city>
        <zip>54-130</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dariusz Janczak, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Dariusz Janczak, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 16, 2020</study_first_submitted>
  <study_first_submitted_qc>September 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2020</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venous Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

